IPN Stock Overview
Operates as a biopharmaceutical company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for IPN from our risk checks.
Ipsen S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €109.80 |
| 52 Week High | €123.70 |
| 52 Week Low | €100.50 |
| Beta | 0.57 |
| 11 Month Change | -4.44% |
| 3 Month Change | 3.20% |
| 1 Year Change | 4.37% |
| 33 Year Change | 23.57% |
| 5 Year Change | n/a |
| Change since IPO | 28.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| IPN | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 1.1% | 3.0% | -0.3% |
| 1Y | 4.4% | 5.7% | 2.5% |
Return vs Industry: IPN underperformed the Austrian Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: IPN exceeded the Austrian Market which returned 2.5% over the past year.
Price Volatility
| IPN volatility | |
|---|---|
| IPN Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.6% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: IPN has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: IPN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 5,325 | David Loew | www.ipsen.com |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Ipsen S.A. Fundamentals Summary
| IPN fundamental statistics | |
|---|---|
| Market cap | €9.05b |
| Earnings (TTM) | €663.90m |
| Revenue (TTM) | €3.44b |
13.6x
P/E Ratio2.6x
P/S RatioIs IPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPN income statement (TTM) | |
|---|---|
| Revenue | €3.44b |
| Cost of Revenue | €618.00m |
| Gross Profit | €2.82b |
| Other Expenses | €2.15b |
| Earnings | €663.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 8.08 |
| Gross Margin | 82.01% |
| Net Profit Margin | 19.33% |
| Debt/Equity Ratio | 9.6% |
How did IPN perform over the long term?
See historical performance and comparison